Press Releases March 31, 2026 08:00 PM

Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026

Resmed Announces Q3 Fiscal 2026 Earnings Release Date and Webcast Details

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
RMD

Resmed, a global leader in health technologies focusing on sleep and respiratory care, will release its Q3 fiscal 2026 earnings on April 30, 2026, after the NYSE closes. Management will discuss results in a webcast, providing financial and operational insights along with forward-looking information.

Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
RMD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Resmed plans to report fiscal Q3 2026 earnings on April 30, 2026, with a webcast for investors and analysts.
  • The company specializes in AI-powered digital health solutions for personalized home healthcare in sleep and breathing.
  • Resmed operates globally, impacting sectors including healthcare technology, medical devices, and digital health services.

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

•Location:https://investor.resmed.com•Date:1:30 p.m. PT / 4:30 p.m. ET•Time:London, Thursday, April 30, 2026, 9:30 p.m. BST•International:Sydney, Friday, May 1, 2026, 6:30 a.m. AEST   

Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.

A replay of the earnings webcast will be accessible on Resmed’s investor relations website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from April 30, 2026, until May 14, 2026, at:

  • U.S.: +1 877.660.6853
  • International: +1 201.612.7415
  • Conference ID: 13759381

About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

For investorsFor media+1 858.221.3304+1 [email protected]@Resmed.com



Risks

  • Earnings results may be influenced by uncertainties in the healthcare technology market and regulatory environment.
  • Forward-looking statements and operational outcomes discussed during the webcast carry inherent risks and uncertainties.
  • Market dynamics in home healthcare technology and global economic factors may affect Resmed's performance and stock response.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026